We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$82.3B
AUM Growth
+$3.23B
(+4.1%)
Cap. Flow
-$7.73B
Cap. Flow
% of AUM
-9.4%
Top 10 Holdings %
Top 10 Hldgs %
24.03%
Holding
2,474
New
201
Increased
562
Reduced
953
Closed
424
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$983M |
| 2 |
Exelon
EXC
|
+$595M |
| 3 |
Broadcom
AVGO
|
+$486M |
| 4 |
CRH
CRH
|
+$387M |
| 5 |
Marvell Technology
MRVL
|
+$274M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$795M |
| 2 |
Norfolk Southern
NSC
|
+$559M |
| 3 |
PPL
PPL Corp
PPL
|
+$355M |
| 4 |
Union Pacific
UNP
|
+$328M |
| 5 |
Cisco
CSCO
|
+$283M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.45% |
| 2 | Financials | 14.25% |
| 3 | Healthcare | 13.09% |
| 4 | Industrials | 10.08% |
| 5 | Consumer Discretionary | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Caribou Biosciences
CRBU
$163M
| $20K | ﹤0.01% |
4,221
-17,068
| -80% | -$105K |
|
1677
CGI
GIB
$15.4B
| $20K | ﹤0.01% |
186
| – | – |
|
1678
Legend Biotech
LEGN
$3.73B
| $20K | ﹤0.01% |
380
-210
| -36% | -$12.7K |
|
1679
Plumas Bancorp
PLBC
$427M
| $20K | ﹤0.01% |
554
-1
| -0.2% | -$36 |
|
1680
Sun Life Financial
SLF
$45.6B
| $20K | ﹤0.01% |
+380
| New | +$20.1K |
|
|
BLUE
1681
DELISTED
bluebird bio
BLUE
| $19K | ﹤0.01% |
759
+416
| +121% | +$10.7K |
|
1682
CoreCivic
CXW
$3.19B
| $19K | ﹤0.01% |
1,275
-3,768
| -75% | -$54.9K |
|
1683
TScan Therapeutics
TCRX
$49.9M
| $19K | ﹤0.01% |
2,551
-1,432
| -36% | -$9.01K |
|
1684
Tecnoglass Holdings Inc.
TGLS
$1.97B
| $19K | ﹤0.01% |
384
-6,824
| -95% | -$314K |
|
|
VBNK
1685
VersaBank
VBNK
$615M
| $19K | ﹤0.01% |
+1,850
| New | +$20.5K |
|
1686
Integra LifeSciences
IART
$1.33B
| $18K | ﹤0.01% |
+534
| New | +$21.4K |
|
1687
Tango Therapeutics
TNGX
$4.72B
| $18K | ﹤0.01% |
2,349
-1,307
| -36% | -$14K |
|
1688
TransUnion
TRU
$15.2B
| $18K | ﹤0.01% |
235
-15
| -6% | -$1.1K |
|
1689
Capricor Therapeutics
CAPR
$242M
| $17K | ﹤0.01% |
+2,693
| New | +$13K |
|
1690
Lyell Immunopharma
LYEL
$348M
| $17K | ﹤0.01% |
396
-224
| -36% | -$9.59K |
|
1691
Tenaya Therapeutics
TNYA
$163M
| $17K | ﹤0.01% |
3,354
-1,853
| -36% | -$8.87K |
|
1692
Allogene Therapeutics
ALLO
$680M
| $16K | ﹤0.01% |
3,861
-2,137
| -36% | -$8.92K |
|
1693
DXP Enterprises
DXPE
$3.07B
| $16K | ﹤0.01% |
312
-1,634
| -84% | -$61.4K |
|
1694
Taysha Gene Therapies
TSHA
$1.82B
| $16K | ﹤0.01% |
5,804
-3,001
| -34% | -$6.25K |
|
|
CTLT
1695
DELISTED
CATALENT, INC.
CTLT
| $16K | ﹤0.01% |
291
-125,362
| -100% | -$6.79M |
|
|
SGMO
1696
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $15K | ﹤0.01% |
23,437
-13,653
| -37% | -$9.9K |
|
1697
Biohaven
BHVN
$2.17B
| $14K | ﹤0.01% |
272
-11
| -4% | -$545 |
|
1698
Core Molding Technologies
CMT
$216M
| $14K | ﹤0.01% |
742
-158
| -18% | -$2.82K |
|
1699
Sabre
SABR
$886M
| $14K | ﹤0.01% |
5,810
+5,274
| +984% | +$17.7K |
|
1700
Sabesp
SBS
$18.9B
| $14K | ﹤0.01% |
4,558
-583
| -11% | -$1.78K |
|
Similar funds
QCM
Lazard Asset Management's Q1 2024 Portfolio in Review
As of Q1 2024, Lazard Asset Management held 2,474 positions worth $82.3B, up 4.1% from $79B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $7.73B in Q1 2024, closing 424 positions and reducing 953 holdings. Its most notable exit was PPL Corp, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Lazard Asset Management opened a new position in GMO US Quality ETF worth $10.8M.
- Lazard Asset Management's largest Q1 2024 buy was GMO US Quality ETF: 362,290 shares worth $10.8M.
- Lazard Asset Management added most to Apple in Q1 2024, an estimated $983M increase.
- Lazard Asset Management's biggest Q1 2024 reduction was Alphabet (Google) Class A, cutting an estimated $795M.
- Lazard Asset Management fully exited PPL Corp in Q1 2024, selling an estimated $355M.
- Lazard Asset Management's ten largest holdings make up 24% of its $82.3B portfolio in Q1 2024.
- Lazard Asset Management opened 201 new positions and closed 424 in Q1 2024.
- Lazard Asset Management's portfolio value rose 4.1% quarter-over-quarter to $82.3B.
Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.